301 results match your criteria: "Terumo Corporation R & D Center[Affiliation]"

Article Synopsis
  • The INSPIRATION-S trial investigated the effects of atorvastatin versus placebo on 90-day outcomes in ICU patients with COVID-19, focusing on complications like thrombosis and mortality.
  • Results showed that atorvastatin users had a slightly lower incidence of severe outcomes compared to placebo (33.1% vs 38.0%), but the difference was not statistically significant.
  • The study indicated a potential benefit of atorvastatin, particularly for patients who began treatment within the first week of symptom onset, with improved functional status noted, although definitive conclusions couldn't be made.
View Article and Find Full Text PDF

Cardiovascular diseases are the leading cause of death worldwide. Although there have been substantial advances over the last decades, recurrent adverse cardiovascular events after myocardial infarction are still frequent, particularly during the first year of the index event. For decades, high-density lipoprotein (HDL) has been among the therapeutic targets for long-term prevention after an ischemic event.

View Article and Find Full Text PDF

Background: Ultrasound guidance increases the success rate of peripheral intravenous catheter placement. However, the longer time required to obtain ultrasound-guided access poses difficulties for ultrasound beginners. Notably, interpretation of ultrasonographic images is considered as one of the main reasons of difficulty in using ultrasound for catheter placement.

View Article and Find Full Text PDF

Derivation and validation of a machine learning-based risk prediction model in patients with acute heart failure.

J Cardiol

June 2023

Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development, Tokyo, Japan.

Article Synopsis
  • The study aims to create a simple risk score, called 4 V-RS, for predicting in-hospital mortality in patients with acute heart failure (AHF) using a machine-learning method (LASSO regression).
  • In both the derivation cohort (REALITY-AHF) and the validation cohort (NARA-HF), the model was found to have a higher predictive ability compared to the existing ADHERE risk model and performed similarly to the GWTG-BNP-Cl-RS model.
  • The 4 V-RS consists of four key variables (systolic blood pressure, blood urea nitrogen, serum chloride, and C-reactive protein) and demonstrates that a simpler model can be just as effective in risk assessment
View Article and Find Full Text PDF

Background:  Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were burdened by low statistical power for clinical outcomes.

Methods:  We performed a systematic review and meta-analysis of RCT comparing FXI inhibitors versus other anticoagulants (enoxaparin or direct oral anticoagulants, DOACs) or versus placebo on top of antiplatelet therapy.

Results:  Eight RCTs testing FXI inhibitors (ISIS 416858, osocimab, abelacimab, milvexian, asundexian) and enrolling 9,216 patients were included.

View Article and Find Full Text PDF

Background: Hypertension imposes substantial health and economic burden worldwide. Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, causing cardiovascular events at higher risk compared with essential hypertension. However, the germline genetic contribution to the susceptibility of PA has not been well elucidated.

View Article and Find Full Text PDF

P2Y Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.

J Am Coll Cardiol

February 2023

Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland; Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland. Electronic address:

Background: It remains unclear whether P2Y inhibitor monotherapy preserves ischemic protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI).

Objectives: We sought to assess the effects of P2Y inhibitor monotherapy after 1-month to 3-month DAPT vs standard DAPT in relation to PCI complexity.

Methods: We pooled patient-level data from randomized controlled trials comparing P2Y inhibitor monotherapy and standard DAPT on centrally adjudicated outcomes after coronary revascularization.

View Article and Find Full Text PDF

Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is an established standard treatment option for chemotherapy-naive patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, of such patients who have received prior treatment with a first- or second-generation EGFR TKI, only approximately half are eligible for osimertinib therapy because its indication as second-line treatment and beyond is limited to metastatic NSCLC that is positive for the T790M resistance mutation of the EGFR gene. This study was initiated at the request of a dedicated network for patients with lung cancer in Japan.

View Article and Find Full Text PDF
Article Synopsis
  • The study utilizes a Bayesian quantile regression (BQR) method to analyze how various cardiovascular risk factors relate to different stages of coronary artery disease (CAD) for specific blood vessels.
  • Data from 1,463 patients was examined, focusing on lumen diameter stenosis (DS) in the left anterior descending (LAD), left circumflex (LCx), and right coronary artery (RCA), using baseline risk factors as input for predictive models.
  • Results indicated that certain symptoms and conditions, like diabetes and angina, were significantly linked to higher DS levels in specific arteries, showcasing the BQR model's effectiveness in understanding the impact of cardiovascular risk factors on CAD.
View Article and Find Full Text PDF

Purpose: To identify disease-specific profiles comprising patient characteristics and imaging biomarkers on contrast-enhanced (CE)-computed tomography (CT) that enable the non-invasive prediction of the hepatopulmonary shunt fraction (HPSF) in patients with hepatocellular carcinoma (HCC) before resin-based transarterial radioembolization (TARE).

Patients And Methods: This institutional review board-approved (EA2/071/19) retrospective study included 56 patients with HCC recommended for TARE. All patients received tri-phasic CE-CT within 6 weeks prior to an angiographic TARE evaluation study using technetium-99m macroaggregated albumin.

View Article and Find Full Text PDF

Background: Statins reduce the incidence of major cardiovascular events, but residual risk remains. The study examined the determinants of atherosclerotic statin nonresponse.

Objectives: This study aimed to investigate factors associated with statin nonresponse-defined atherosclerosis progression in patients treated with statins.

View Article and Find Full Text PDF

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.

Blood Adv

June 2023

Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany.

Patients with precursor B-cell acute lymphoblastic leukemia (pB-ALL) who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT), have relapsed more than once, or are resistant upfront have a dismal prognosis. CD19-targeted chimeric antigen receptor (CAR) T cells have evolved as potent immune therapies. Tisagenlecleucel (Tisa-cel) is a commercially available autologous CD19-directed CAR T-cell product.

View Article and Find Full Text PDF

Aims: Data on sex and left ventricular assist device (LVAD) utilization and outcomes have been conflicting and mostly confined to US studies incorporating older devices. This study aimed to investigate sex-related differences in LVAD utilization and outcomes in a contemporary European LVAD cohort.

Methods And Results: This analysis is part of the multicentre PCHF-VAD registry studying continuous-flow LVAD patients.

View Article and Find Full Text PDF
Article Synopsis
  • The phase 3 VELIA trial tested the effectiveness of veliparib combined with carboplatin and paclitaxel as a treatment and maintenance option for patients with high-grade serous ovarian carcinoma.
  • In a subgroup analysis of 78 Japanese patients, those receiving vtreatment with veliparib showed a median progression-free survival of 27.4 months compared to 19.1 months for the control group, although the results were not statistically significant.
  • The study noted differences in the rates of severe side effects between Japanese and non-Japanese patients, suggesting the need for tailored management strategies during treatment.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigated outcomes of left ventricular assist devices (LVADs) in older patients, specifically those age 50 and above, to understand how age impacts mortality and complications after continuous-flow LVAD implantation.
  • Among 562 patients analyzed, those aged 65 and older had a significantly higher risk of mortality and major bleeding events compared to younger patients, with a 10-year increase in age correlating to greater risks.
  • Interestingly, older patients experienced fewer device-related infections needing antibiotics and showed similar rates of heart failure hospitalizations and other complications compared to younger groups.
View Article and Find Full Text PDF
Article Synopsis
  • Recent studies are examining short-term dual antiplatelet therapy after placing newer-generation drug-eluting stents (DES), but the specific biological responses in humans are still unclear.
  • This research compared early pathological responses of abluminal biodegradable polymer-coated (BP-) DES and circumferential durable polymer-coated (DP-) DES using 38 coronary lesions from autopsies.
  • The findings suggest that BP-DES showed greater strut coverage compared to DP-DES shortly after implantation, and while both stent types had low inflammation, BP-DES potentially allow for faster healing with endothelial coverage developing within days.
View Article and Find Full Text PDF

Background: The next-generation ACURATE neo2 transcatheter aortic valve was designed for simplified implantation and to mitigate the risk of paravalvular leak (PVL) compared to the earlier device.

Aims: To collect clinical outcomes and device performance data, including echocardiography and 4-dimensional computed tomography (4D-CT) data, with the ACURATE neo2 transcatheter heart valve in patients with severe aortic stenosis (AS).

Methods: ACURATE neo2 PMCF is a single-arm, multicentre study of patients with severe AS treated in routine clinical practice.

View Article and Find Full Text PDF

Why inflammation is common in ileal pouches with ulcerative colitis (UC) is unclear. We therefore clarified the morphological changes in pouches and afferent limbs (AL) of patients with UC and explored the relationship between these findings. We evaluated the morphological findings (histological and endoscopic inflammation as the Pouchitis Disease Activity Index [PDAI] histology subscore [hPDAI] and endoscopy subscore [ePDAI], inflammatory bowel disease [IBD]-specific findings using the IBD score [S], colonic metaplasia using the colonic metaplasia score [CMS], and goblet cell [GC] ratio) in the pouch and AL of patients with UC.

View Article and Find Full Text PDF

Antigen stabilizing hydrogels based on cyclodextrins and polyethylene glycol act as type-2 adjuvants with suppressed local irritation.

Eur J Pharm Biopharm

December 2022

Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Electronic address:

Recent viral pandemics have increased global demand for vaccines. However, the supply of effective and safe vaccine not only to developed countries but also developing countries with inadequate storage equipment is still challenging due to the lack of robust systems which improve the efficacy and the stability of vaccines with few side effects. In our previous study, polypseudorotaxane (PPRX) hydrogels based on cyclodextrin (CyD) and polyethylene glycol (PEG) significantly improved the stability of antibody preparations and showed no serious adverse effects after subcutaneous injection, suggesting the possibility as safe vaccine formulations to stabilize an antigen protein.

View Article and Find Full Text PDF

Background: Neighborhood disadvantage is associated with a higher risk of sudden cardiac death. However, autopsy findings have never been investigated in this context. Here, we sought to explore associations between neighborhood disadvantage and cardiovascular findings at autopsy in cases of sudden death in the State of Maryland.

View Article and Find Full Text PDF
Article Synopsis
  • Inebilizumab is an anti-CD19 antibody effective for treating neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies, showing significant long-term benefits in reducing disease activity.
  • In the N-MOmentum study, treatment led to quick and sustained depletion of B-cells and plasma-cells, with deeper depletion linked to better clinical outcomes, including lower attack rates and fewer new MRI lesions.
  • The study concludes that while inebilizumab rapidly depletes B-cells, the extent of this depletion correlates with improved stability and reduced severity of NMOSD symptoms over time.
View Article and Find Full Text PDF

Background: As a preventive procedure, minimizing periprocedural risk is crucially important during left atrial appendage closure (LAAC). Methods: We included consecutive patients receiving LAAC at nine centres and assessed the relationship between baseline characteristics and the acute procedural outcome. Major procedural complications were defined as all complications requiring immediate invasive intervention or causing irreversible damage.

View Article and Find Full Text PDF

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.

Oncologist

January 2023

Medical Oncology, Breast Unit, Royal Marsden NHS Foundation Trust, London, UK.

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).

View Article and Find Full Text PDF

Background And Aims: Sustained neurohormonal activation plays a central role in the progression of heart failure (HF). Other endocrine axes may also be affected. It was the aim of this study to examine the endocrine profile (thyroid, parathyroid, glucocorticoid, and sex hormones) in a contemporary sample of patients with HF and reduced ejection fraction (EF) on established disease-modifying therapy.

View Article and Find Full Text PDF

Background: Coronary artery perforation is a feared complication of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) and often leads to serious adverse clinical events.

Aims: We sought to develop a risk score to predict clinical coronary artery perforation in patients undergoing CTO PCI.

Methods: We analysed clinical and angiographic parameters from 9,618 CTO PCIs in the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO).

View Article and Find Full Text PDF